Altimmune, Inc.
corporate_fare Company Profile
Altimmune, Inc. (NASDAQ:ALT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for ALT at importance 7 or higher on its 1–10 market-impact scale.
Recent high-impact activity:
- Altimmune Reports Strong Clinical Progress for Pemvidutide and Secures Significant Financing
- Altimmune's Pemvidutide Gets FDA Breakthrough Status for MASH, Bolstered by $274M Cash
- Altimmune Raises $75M via Dilutive Offering at Significant Discount to Fund Clinical Trials
Financial Snapshot
Fiscal year ended December 31, 2025
Revenue
$41K
Net Income
-$88.09M
Diluted EPS
-$1.00
Op. Cash Flow
-$67.53M
Operating Income
-$94.49M
Cash & Equivalents
$43.76M
Total Debt
$34.29M
Debt / Equity
0.15×
Net Margin
-2148.61×
Shares Outstanding
110.88M sh
Source: 10-K · filed 2026-03-06 · accession 0001326190-26-000018
show_chartPrice Chart
Loading chart...
feed ALT - Filings & News (Page 2)
ALT
Mar 06, 2026, 7:56 AM EST
Price at Filing:
$3.60
Real-time Price:
$1.35
Change:
-$2.25 (-62%)
Market Cap:
$258.804M
ALT
Mar 05, 2026, 7:00 AM EST
Price at Filing:
$4.24
Real-time Price:
$1.35
Change:
-$2.89 (-68%)
Market Cap:
$258.804M
ALT
Jan 28, 2026, 5:23 PM EST
Price at Filing:
$5.19
Real-time Price:
$1.35
Change:
-$3.84 (-74%)
Market Cap:
$258.804M